RTI Biologics Launches New Line of Biologic Implants at Americas Hernia
Society’s 15th Annual Hernia Repair Conference, March 13-16
Company will host symposium luncheon on March 13
ALACHUA, Fla -- March 12, 2013
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and
other biologic implants, is launching a new line of biologic implants used in
hernia repair procedures at the Americas Hernia Society’s 15^th Annual Hernia
Repair Conference held at JW Marriott Grande Lakes, Orlando, Fla., March
13-16. The implants will be distributed directly by the company’s new Surgical
Specialties business unit.
Tutopatch™ bovine pericardium and Tutomesh™ fenestrated bovine pericardium are
non-crosslinked acellular collagen matrices that offer a safe and natural
biologic option for hernia repair. The implants offer equivalent strength^1 to
the leading implant in the market and are sterilized through RTI’s Tutoplast^®
Tissue Sterilization Process. The Tutopatch and Tutomesh implants are
clinically proven and have been implanted by surgeons in Europe for more than
Cortiva™ allograft dermis offers high mechanical strength^2,3, rapid cellular
repopulation^4,5,6 and features a faster rehydration time compared with other
dermis grafts (rehydrating in 30 seconds on average)^7. Dermis is collagenous
connective tissue with three-dimensional intertwined fibers. The Cortiva
implant is also sterilized through RTI’s Tutoplast Tissue Sterilization
Process rendering non-crosslinked acellular dermal matrix that retain
mechanical properties of native dermis.
“We are excited to begin direct distribution of Tutopatch and Tutomesh bovine
pericardium and Cortiva allograft dermis through our newly developed
distribution force for Surgical Specialties,” said Brian K. Hutchison, RTI
president and CEO. “Surgeons in need of biologics for hernia repair can expect
safe, quality implants from a provider they trust. We will be filling out our
hernia portfolio in the coming months with the introduction of our porcine
The Tutoplast Tissue Sterilization Process is a validated chemical
sterilization process that thoroughly penetrates tissue, removing antigenicity
and inactivating pathogens. Terminal sterilization using low dose gamma
irradiation achieves a sterility assurance level (SAL) of 10^-6.
AHS Luncheon Symposium
In addition to launching the implant line at the AHS conference, RTI will also
host a luncheon presentation and discussion on Wednesday, March 13 from 12 to
1 p.m. featuring David Nocca, M.D., Ph.D. from the Department of Digestive
Surgery at the University Hospital of Montpellier in Montpellier, France.
Nocca will present “Biosurgical Technology and Technique-Based Considerations
for Ventral Hernia Repair.”
Tutopatch and Tutomesh bovine pericardium and Cortiva allograft dermis are
currently available for distribution. For further information, visit the RTI
booth, #207, at the Annual Hernia Repair Conference or contact an RTI
representative at (877) 612-4287.
^1Data on file at RTI Biologics, Inc.
^2Data on file – Doc #7042. Benchtop Testing comparing Cortiva to Standard
Tutoplast Sterilized Dermis 2013.
^3Hollinsky C, Sandberg S. Measurement of the tensile strength of the ventral
abdominal wall in comparison with scar tissue. Clinical Biomechanics. 22
(2007) 88 – 92.
^4Data on file – 4 & 8 week rat model comparing Cortiva1mm to Standard1mm
Tutoplast Sterilized Dermis 2012.5.
^5Deeken CR, Melman L, Jenkins ED, et al. Histologic and biomechanical
evaluation of crosslinked and non-crosslinked biologic meshes in a porcine
model of ventral incisional hernia repair. J Am Coll Surg.
2011 May; 212(5):880-8.
^6Novitsky YW, Rosen MJ. The biology of Biologics: Basic Science and Clinical
Concepts. Plast Reconstr Surg. 2012 Nov;130(5 Suppl 2): 9S-17S.
^7Data on file – Rehydration study comparing Cortiva to Standard Tutoplast
Sterilized Dermis 2013.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for
surgeries around the world with a commitment to advancing science, safety and
innovation. RTI prepares human donated tissue and xenograft tissue for
transplantation through extensive testing and screening, precision shaping and
using proprietary, validated processes. These allograft and xenograft implants
are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for
biologics – from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral inactivation
steps. These processes — BioCleanse®, Tutoplast® and Cancelle® SP DBM — have a
combined record of more than four million implants distributed with zero
incidence of implant-associated infection. These processes have been validated
by tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with
international locations in Germany and France. The company is accredited by
the American Association of Tissue Banks in the United States and is a member
RTI Biologics Inc.
Jenny Highlander, APR, 386-418-8888, ext. 4149
Manager, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.